CHENGDU, China, July 14, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH), congratulates its partner BioAge Labs, Inc. ("BioAge", NASDAQ: BIOA), a clinical-stage biopharmaceutical company developing therapeutic product candidates for...
Hence then, the article about hitgen partner bioage labs doses first participant in phase 2 trial of bge 102 a novel oral nlrp3 inhibitor for cardiovascular risk reduction was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( HitGen Partner BioAge Labs Doses First Participant in Phase 2 Trial of BGE-102, a Novel Oral NLRP3 Inhibitor for Cardiovascular Risk Reduction )
Also on site :
- Olympic Gymnastics Legend, Who Scored the World’s First Perfect 10, Relives Her Greatest Performance 50 Years Later
- ABBA’s Björn Ulvaeus Talks AI Training at United Nations Summit: Artists ‘Deserve a Place at the Table’
- Mississippi’s history of racism is a talking point as investigation unfolds in the mysterious death of Nolan Xavier Wells